Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients.

Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients. F1000Prime Rep. 2015;7:21 Authors: Timsit JF, Chemam S, Bailly S Abstract The potential of the systemic antifungal treatment of non-immunocompromised patients with sepsis, extra-digestive Candida colonization and multiple organ failure is unknown, although it represents three out of four antifungal treatments prescribed in intensive care units. It may allow an early treatment of invasive fungal infection at incubation phase, but exposes patients to unnecessary antifungal treatments with subsequent costs and antifungal selection pressure. As early diagnostic tests for invasive candidiasis are still considered insufficient, the potential of this strategy needs to be demonstrated by a randomized controlled trial. Such a trial is currently ongoing. PMID: 25750739 [PubMed]
Source: F1000 Medicine Reports - Category: Biomedical Science Tags: F1000Prime Rep Source Type: research